表皮生長因子受體 (EGFR) 外顯子20 插入突變的局部晚期或轉移性非小細胞肺癌 (NSCLC)

Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor; Antineoplastic Agent, MET Inhibitor; Antineoplastic Agent, Monoclonal Antibody

Distribution: 5.13 L.
Half-life elimination: 11.3 days.
Excretion: 360 mL/day.

Hypersensitivity to amivantamab or any component of the formulation.

Based on the mechanism of action and data from animal models, in utero exposure to amivantamab may cause fetal harm.

breastfeeding is not recommended by the manufacturer during therapy and for 3 months after the last amivantamab dose.

>10%: edema (27%), paronychia (50%), pruritus (18%), skin rash (84%), decreased serum albumin (79%), decreased serum magnesium (27%), decreased serum phosphate (33%), decreased serum potassium (26%), decreased serum sodium (27%), increased gamma-glutamyl transferase (27%), increased serum glucose (56%), constipation (23%), nausea (36%), stomatitis (26%), vomiting (22%), hemorrhage (19%), lymphocytopenia (36%), increased serum alanine aminotransferase (38%), increased serum alkaline phosphatase (53%), increased serum aspartate aminotransferase (33%), fatigue (33%), musculoskeletal pain (47%), increased serum creatinine (46%), cough (25%), dyspnea (37%), infusion related reaction (64%).

Non–small cell lung cancer, locally advanced or metastatic, with epidermal growth factor receptor exon 20 insertion mutation:
Patients <80 kg:
Week 1: IV: 1,050 mg split over days 1 and 2 (350 mg on day 1 and 700 mg on day 2).
Weeks 2 to 4: IV: 1,050 mg once weekly.
Subsequent infusions: IV: 1,050 mg once every 2 weeks (starting at week 5) until disease progression or unacceptable toxicity.
Patients ≥80 kg:
Week 1: IV: 1,400 mg split over days 1 and 2 (350 mg on day 1 and 1,050 mg on day 2).
Weeks 2 to 4: IV: 1,400 mg once weekly.
Subsequent infusions: IV: 1,400 mg once every 2 weeks (starting at week 5) until disease progression or unacceptable toxicity.

---

Suggested dose adjustments for Rybrevant adverse reactions

baseline weight	first dose	first dose reduction	second dose reduction	third dose reduction
<80 kg	1050mg	700mg	350mg	Discontinue amivantamab
≥ 80kg	1400mg	1050mg	700mg	Discontinue amivantamab